Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
T Fiolet, Y Kherabi, CJ MacDonald, J Ghosn… - Clinical Microbiology …, 2022 - Elsevier
Background Vaccines are critical cost-effective tools to control the coronavirus disease 2019
(COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory …
(COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory …
mRNA-based therapeutics: powerful and versatile tools to combat diseases
S Qin, X Tang, Y Chen, K Chen, N Fan… - Signal transduction and …, 2022 - nature.com
The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide
range of incurable diseases. Recent rapid advances in biotechnology and molecular …
range of incurable diseases. Recent rapid advances in biotechnology and molecular …
Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
The emergence of the SARS-CoV-2 variant of concern Omicron (Pango lineage B. 1.1. 529),
first identified in Botswana and South Africa, may compromise vaccine effectiveness and …
first identified in Botswana and South Africa, may compromise vaccine effectiveness and …
Protection of BNT162b2 vaccine booster against Covid-19 in Israel
Abstract Background On July 30, 2021, the administration of a third (booster) dose of the
BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) was approved in Israel for persons …
BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) was approved in Israel for persons …
[HTML][HTML] Features, evaluation, and treatment of coronavirus (COVID-19)
M Cascella - 2020 - ncbi.nlm.nih.gov
Objectives: Screen individuals based on exposure and symptom criteria to identify potential
COVID-19 cases. Identify the clinical features and radiological findings expected in patients …
COVID-19 cases. Identify the clinical features and radiological findings expected in patients …
Duration of protection against mild and severe disease by Covid-19 vaccines
Background Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), the virus that causes coronavirus disease 2019 (Covid-19), have been used since …
2), the virus that causes coronavirus disease 2019 (Covid-19), have been used since …
Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection
Background The duration and effectiveness of immunity from infection with and vaccination
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are relevant to …
against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are relevant to …
Protection and waning of natural and hybrid immunity to SARS-CoV-2
Background Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
provides natural immunity against reinfection. Recent studies have shown waning of the …
provides natural immunity against reinfection. Recent studies have shown waning of the …
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
The Omicron variant of SARS-CoV-2 is causing a rapid increase in infections across the
globe. This new variant of concern carries an unusually high number of mutations in key …
globe. This new variant of concern carries an unusually high number of mutations in key …
Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar
Background Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and
the emergence of the omicron (or B. 1.1. 529) variant of the severe acute respiratory …
the emergence of the omicron (or B. 1.1. 529) variant of the severe acute respiratory …